Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 19, 2021 08:05 ET | Source: Metacrine, Inc.

Metacrine to Present New Preclinical Data on MET642 in Inflammatory Bowel Disease at Digestive Disease Week 2021 Virtual Meeting

SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal...
May 18, 2021 08:05 ET | Source: Metacrine, Inc.

Metacrine Achieves Enrollment Target for MET642 Phase 2a Trial Interim Analysis

Interim data from the first 60 patients with NASH on track to be reported in the fourth quarter of 2021Enrollment continuing for up to 180 patients, with full topline results expected to be reported...
May 13, 2021 16:05 ET | Source: Metacrine, Inc.

Metacrine Accelerates MET409 Clinical Development Milestone and Reports First-Quarter 2021 Results

• Topline results from a Phase 2a trial of MET409 in combination with empagliflozin in patients with NASH and type 2 diabetes now expected in the fourth quarter of 2021 • Interim data from the...
May 11, 2021 08:05 ET | Source: Metacrine, Inc.

Metacrine to Present at 2021 RBC Global Healthcare Conference

SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal...
April 05, 2021 16:05 ET | Source: Metacrine, Inc.

Metacrine Appoints Dr. Julia C. Owens to Its Board of Directors

SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and...
March 18, 2021 06:30 ET | Source: Metacrine, Inc.

Metacrine Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

Interim Data from the Phase 2a Trial of MET642 in NASH Patients On-Track to be Reported in the Fourth Quarter of 2021 Topline Results from a Phase 2a Trial of MET409 in Combination with Empagliflozin...
March 11, 2021 06:30 ET | Source: Metacrine, Inc.

Metacrine to Present Final Results from Phase 1 Trial of MET642, an Optimized FXR Agonist, at the 2021 NASH-TAG Conference

SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients...
March 11, 2021 06:15 ET | Source: Metacrine, Inc.

Metacrine Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call

SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients...
March 09, 2021 06:30 ET | Source: Metacrine, Inc.

Metacrine Initiates Phase 2a Trial of MET642 for the Treatment of Patients with NASH

SAN DIEGO, March 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients...
March 02, 2021 06:30 ET | Source: Metacrine, Inc.

Metacrine to Present at H.C. Wainwright 2021 Global Life Sciences Conference

SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right